Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

By GlobeNewswire,  May 17, 2019, 08:00:00 AM EDT

Presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

SYDNEY, Australia, May 17, 2019 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces more mature data relating to Part B of its ongoing phase I TACTI-mel clinical study of the Company's lead product candidate, eftilagimod alpha ("efti" or "IMP321") in patients with melanoma. The data was presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 in London on May 17, 2019 by Dr Frédéric Triebel, Chief Scientific Officer and Chief Medical Officer of Immutep.

The ongoing TACTI-mel trial evaluates the combination of efti with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 24 patients with unresectable or metastatic melanoma. It is a multi-center, open label clinical trial that involves four cohorts of six patients, each cohort testing different dosages of efti, including 1 milligram (mg), 6 mg and 30 mg, in combination with pembrolizumab. Part B of the study includes a cohort of 6 patients at 30 mg of efti in combination with pembrolizumab, starting at cycle 1, day 1 and with a treatment duration of 12 months.

Consistent with previous data reported at 6 months of combination treatment (March 2019), patients in Part B continue to report positive results in terms of tumour reductions after 9 months of treatment. Four patients are continuing to receive treatment. No new safety data or data from Part A of the study have been reported. The key findings from Part B are:

  Part B (starting cycle 1, day 1 of pembro therapy)

Overall Response Rate (ORR) 50%
Disease Control Rate (DCR) 66%

The full presentation slides from the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 can be accessed via Immutep's website at www.immutep.com.

About the TACTI-mel clinical trial

The ongoing TACTI-mel (Two ACTive Immunotherapies in melanoma) Phase I clinical trial is a multicenter, open-label study evaluating the combination of eftilagimod alpha ("efti") with pembrolizumab, in unresectable or metastatic melanoma patients that have had either a suboptimal response or had disease progression with pembrolizumab monotherapy (clinicaltrials.gov identifier NCT 02676869).

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ ( IMMP ) in the United States. Further information can be found on the Company's website www.immutep.com or by contacting:

U.S. Investors:

Jay Campbell, Chief Business Officer, Immutep Limited

+1 (917) 860-9404; jay.campbell@immutep.com

Garth Russell, LifeSci Advisors

+1 (646) 876-3613; garth@lifesciadvisors.com

Australian Investors/Media:

Matthew Gregorowski, Citadel-MAGNUS

+61 2 8234 0105; mgregorowski@citadelmagnus.com


Source: Immutep Limited

This article appears in: News Headlines

Referenced Stocks: IMMP

Today's Market Activity

NASDAQ 7750.84
-34.88  ▼  0.45%
DJIA 25776.61
-100.72  ▼  0.39%
S&P 500 2856.27
-8.09  ▼  0.28%
Data as of May 22, 2019